Stock Track | REMEGEN Plummets 5.22% Intraday as US-China Regulatory Barriers Escalate for Biotech Sector

Stock Track06-03

REMEGEN's stock price plummeted 5.22% during intraday trading on Wednesday, extending recent downward pressure on the innovative drug company.

The sharp decline comes amid escalating regulatory barriers between the US and China that are undermining the valuation logic for Chinese biotech firms. US legislators recently proposed including biotechnology in the scope of the COINS Act, which would restrict American capital from flowing into Chinese innovative drug companies. Simultaneously, market rumors suggest domestic regulators plan to impose pre-approval requirements on overseas business development transactions for innovative drug firms.

These dual regulatory pressures have created significant headwinds for the sector, with additional selling pressure coming from institutional investors reducing holdings and ETF funds experiencing consecutive net outflows. The broader biotech sector showed similar weakness during the trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119161661?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 13:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119161661","market":"nz","top_or_hot":-1,"title":"Stock Track | REMEGEN Plummets 5.22% Intraday as US-China Regulatory Barriers Escalate for Biotech Sector","media":"Stock Track","content":"<p>REMEGEN's stock price plummeted 5.22% during intraday trading on Wednesday, extending recent downward pressure on the innovative drug company.</p><p>The sharp decline comes amid escalating regulatory barriers between the US and China that are undermining the valuation logic for Chinese biotech firms. US legislators recently proposed including biotechnology in the scope of the COINS Act, which would restrict American capital from flowing into Chinese innovative drug companies. Simultaneously, market rumors suggest domestic regulators plan to impose pre-approval requirements on overseas business development transactions for innovative drug firms.</p><p>These dual regulatory pressures have created significant headwinds for the sector, with additional selling pressure coming from institutional investors reducing holdings and ETF funds experiencing consecutive net outflows. The broader biotech sector showed similar weakness during the trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | REMEGEN Plummets 5.22% Intraday as US-China Regulatory Barriers Escalate for Biotech Sector</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | REMEGEN Plummets 5.22% Intraday as US-China Regulatory Barriers Escalate for Biotech Sector\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-03 13:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>REMEGEN's stock price plummeted 5.22% during intraday trading on Wednesday, extending recent downward pressure on the innovative drug company.</p><p>The sharp decline comes amid escalating regulatory barriers between the US and China that are undermining the valuation logic for Chinese biotech firms. US legislators recently proposed including biotechnology in the scope of the COINS Act, which would restrict American capital from flowing into Chinese innovative drug companies. Simultaneously, market rumors suggest domestic regulators plan to impose pre-approval requirements on overseas business development transactions for innovative drug firms.</p><p>These dual regulatory pressures have created significant headwinds for the sector, with additional selling pressure coming from institutional investors reducing holdings and ETF funds experiencing consecutive net outflows. The broader biotech sector showed similar weakness during the trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1119161661","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119161661","pubTimestamp":1780463468,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"REMEGEN's stock price plummeted 5.22% during intraday trading on Wednesday, extending recent downward pressure on the innovative drug company.The sharp decline comes amid escalating regulatory...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"个股追踪|美中生物科技板块监管壁垒升级REMEGEN盘中暴跌5.22%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"REMEGEN's stock price plummeted 5.22% during intraday trading on Wednesday, extending recent downward pressure on the innovative drug company.The sharp decline comes amid escalating regulatory barriers between the US and China that are undermining the valuation logic for Chinese biotech firms. US legislators recently proposed including biotechnology in the scope of the COINS Act, which would restrict American capital from flowing into Chinese innovative drug companies. Simultaneously, market rumors suggest domestic regulators plan to impose pre-approval requirements on overseas business development transactions for innovative drug firms.These dual regulatory pressures have created significant headwinds for the sector, with additional selling pressure coming from institutional investors reducing holdings and ETF funds experiencing consecutive net outflows. The broader biotech sector showed similar weakness during the trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119161661","isCrawlerRequest":true}